RPCEC00000408已完成未知
Immunogenicity evaluation of the heterologous combination of two doses of SINOPHARM and one dose of SOBERANA Plus: a post-authorization study for emergency use (COVID-19) - Sinopharm-SOBERANA COVID-Cienfuegos
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 202
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Prevention
入排标准
- 年龄范围
- 19 years 至 none（—）
- 性别
- All
入选标准
- •1.- Subjects with 19 years or more, who were eligible for vaccination with SINOPHARM and SOBERANA Plus in the province of Cienfuegos.
- •2.- Subjects who give informed consent for blood extraction at the scheduled times.
排除标准
- •1.- Pregnancy, puerperium or lactation.
- •2.- Subjects with a history of having suffered from COVID-19
研究者
相似试验
招募中
4 期
Safety and Immunogenicity of heterologous or homologous booster after complete vaccination against COVID-19.Covid19D012141RBR-5y9y7p7Secretaria Municipal de Saúde do Rio de Janeiro
已完成
不适用
Safety of Malaria vaccines in Gambian infantsPaediatricsMalariaPACTR201401000363170niversity of Oxford36
已完成
不适用
Safety of Malaria vaccines in Gambian childrePaediatricsMalariaPACTR201204000362870niversity of Oxford36
Unknown
不适用
Safety of Malaria vaccines in Gambian adults , children and infantsMalariaPACTR201008000221638Oxford University, Jenner Institute52
已完成
不适用
Immunogenicity and Safety Outcome of Homologous and Heterologous Prime-boost of Inactivated Vaccine and Replication-defective Viral Vectors Vaccine Against SARS-CoV2 among Hemodialysis Patients: An Observational Prospective Cohort TrialTCTR20220516002Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand130